Experience of Treatment with Noliprel in Hypertensive Patients with Type 2 Diabetes in Ukraine (Research Review)

Yu.N. Sirenko, O.L. Rekovets

Abstract


This article focuses on the evaluation of the results of seven Noliprel studies in hypertensive patients with type 2 diabetes, conducted in Ukraine: PRAKTIK, VEKTOR ZHYZNI, SKIF, SKIF-2, DIAGNOZ, STATUS, UNIA. Total 17 265 patients were included. In 94 % of diabetic patients arterial hypertension has been identified. The mean reduction of office blood pressure (BP) in all studies was 36.7/17.6 mm Hg. Achieving target BP level was 77 %. Albuminuria in patients with type 2 diabetes and hypertension was determined in 3 of the 7 studies: STATUS (88.8 %), PRAKTIK (30.8 %) and SKIF (71 %). On average, the level of albuminuria in the study was 63.53 %. Glomerular filtration rate (GFR) less than 60 mL/min was determined in the PRAKTIK study (31.3 % patients), SKIF — 2 (18.4 % of patients). On average GFR less than 60 mL/min in patients with type 2 diabetes and hypertension was 24.7 %. Hypertrophy of left ventricle was diagnosed in 87.1 % of patients. In Ukraine, in patients with type 2 diabetes, there is poor control of blood pressure in patients with high risk of cardiovascular complications. The main causes of poor blood pressure control are medical inertia, a lack of rational purpose of fixed combinations and appointment of adequate doses of medication. A total in 25 patients in seven trials among 17 265 patients, included into the study, adverse effects were observed, the rate of adverse events was 0.13 %. The drug was withdrawn in 0.02 % of cases.


Keywords


Noliprel forte; Noliprel Bi-forte; efficiency; tole-rance

References


Маньковский Б.Н. Распространенность артериальной гипертензии и контроль артериального давления у больных сахарным диабетом 2-го типа: результаты исследования «ДИАГНОЗ» // Ліки України. — 2011. — № 6(152) — С. 40-44.

Маньковский Б.Н., Иванов Д.Д. Влияние антигипертензивной терапии на функцию почек у больных сахарным диабетом 2-го типа: результаты проспективного исследования «СКИФ-2» // Ліки України. — 2010. — № 8(144). — С. 28-32.

Маньковский Б.Н., Иванов Д.Д. Распространенность поражения почек у больных сахарным диабетом 2-го типа, по данным эпидемиологического исследования «СКИФ» // Серце і судини. — 2009. — № 4. — С. 45-49.

Свищенко Е.П., Ярынкина Е.А. Пациенты с артериальной гипертензией и сахарным диабетом 2-го типа: в поисках оптимальной антигипертензивной терапии // Ліки України. — 2012. — № 10(166). — С. 8-12.

Свищенко Е.П., Ярынкина Е.А. Эффективность антигипертензивной терапии фиксированной комбинацией периндоприла 10 мг и индапамида 2,5 мг в открытом многоцентровом исследовании «ВЕКТОР ЖИЗНИ» у больных с плохо контролируемой артериальной гипертензией на фоне сахарного диабета 2-го типа // Ліки України. — 2011. — № 8(154). — С. 68-76.

Сиренко Ю.Н., Маньковский Б.Н., Радченко А.Д., Кушнир С.Н. Результаты проспективного открытого исследования по оценке антигипертензивной эффективности и переносимости нолипрела би-форте у пациентов с неконтролируемой артериальной гипертензией и сахарным диабетом 2-го типа (исследование ПРАКТИК) // Артеріальна гіпертензія. — 2012. — № 4(24). — С. 9-23.

Сиренко Ю.Н., Радченко А.Д., Слащева Т.Г. Стратификация риска пациентов с артериальной гипертензией и сахарным диабетом 2-го типа: результаты украинского многоцентрового обсервационного исследования СТАТУС // Артеріальна гіпертензія. — 2014. — № 2(34). — С. 35-45.

Сиренко Ю.Н., Рековец О.Л., Амосова Е.Н., Андриевская С.А., Дзяк Г.В., Багрий А.Э., Дядык А.И., Целуйко В.И., Андреев Е.В., Ганюченко В.В., Ханюков А.А., Приколота О.А., Говорова О.B. Антигипертензивная эффективность фиксированной низкодозовой комбинации периндоприла и индапамида у больных с артериальной гипертензией I–II степени (результаты многоцентрового исследования «UNIA» — Ukrainian Noliprel study In Arterial hypertension) // Український кардіологічний журнал. — 2006. — № 2. — С. 67-74.

Сіренко Ю.М. Артеріальна гіпертензія (посібник для лікарів). — К.: Морион, 2002. — 201 с.

Современная модель для прогнозирования сердечно-cосудистого риска у пациентов с сахарным диабетом 2-го типа // Ліки України. — 2011. — № 6. — С. 34-40.

Целуйко В.И., Чернышов В.А., Малая Л.Т. Метаболи-ческий синдром Х. — Харків: Гриф, 2002. — 250 с.

2007 European Society of Hypertension — European Society of Cardiology guidelines for management of arterial hypertension // J. Hypertension. — 2007. — Vol. 25. — P. 1105-1187.

2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Journal of Hypertension. — 2013. — Vol. 31. — P. 1281-1357.

Andrejak M., Zannad F., Laville M., Duru G., Mourad J.J., Waeber B. Evaluation of different approaches to the treatment of arterial hypertension: combination treatment with low dose perindopril/indapamide versus sequential treatment of stepped-dose treatment // Therapie. — 2003. — Vol. 4. — P. 351-352.

Arima H., Anderson C., Omae T. et al. PROGRESS Collaborative Group. Effects of blood pressure lowering on major vascular events among patients with isolated diastolic hypertension: the perindopril protection against recurrent stroke study (PROGRESS) trial // Stroke. — 2011. — Vol. 42(8). — P. 2339-2341.

Asmar R.G., London G.M., O’Rourke M.E., Mallion J.M., Romero R., Rahn K.H., Trimarco B., Fitzgerald D., Hedner T., Duprez D., De Leeuw P.W., Sever P., Battegay E., Hitzenberger G., de Luca N., Polonia P., Benetos A., Chastang C., Ollivier J.P., Safar M.E.; REASON Project Investigators (pREterax in regression of Arterial Stiffness in a contrOlled double-bliNd Study). Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination // J. Hypertens. Suppl. — 2001. — Vol. 4. — S15-20.

Castaigne A., Chalmers J., Morgan T. et al. Efficacy and safety of an oral fixed low-dose perindopril 2 MG/indapamide 0.625 MG combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension // Clin. Exp. Hypertens. — 1999. — Vol. 7. — P. 1097-1110.

Chalmers J., Castaigne A., Morgan T., Chastang C. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients // J. Hypertens. — 2000. — Vol. 3. — P. 327-337.

Dahlof B., Gosse P., Gueret P. et al. on behalf of the PICXEL investigators. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study // J. Hypertens. — 2005. — Vol. 11. — P. 2063-2070.

Dahlof B. Further evidence for low-dose combinations in patients with left ventricular hypertrophy // J. Hum. Hypertens. — 2005. — Vol. 19, Suppl. 1. — S9-14.

Dahlöf B., Gosse P., Guéret P. et al. PICXEL Investigators. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study // J. Hypertens. — 2005. — Vol. 23(11). — P. 2063-2070.

de Leeuw P.W. Very-low-dose combination of perindopril and indapamide as a novel strategy in first-line management of hypertension // J. Hypertens Suppl. — 2001. —Vol. 3. — S. 41-45.

de Luca N., Asmar R.G., London G.M. et al. REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects // J. Hypertens. — 2004. — Vol. 8. — P. 1623-1630.

de Luca N., Mallion J.M., O’Rourke M.F. et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study // Am. J. Hypertens. — 2004. — Vol. 8. — P. 660-667.

Effects of perindopril-indapamide on left ventricular diastolic function and mass in patients with type 2 diabetes: the ADVANCE Echocardiography Substudy. ADVANCE Echocardiography Substudy Investigators; ADVANCE Collaborative Group // J. Hypertens. — 2011. — Vol. 29(7). — P. 1439-1447.

Gosse P., Dubourg O., Gueret P., De Simone G. et al. Efficacy of very low dose perindopril 2 mg/indapamide 0.625 mg combination on left ventricular hypertrophy in hypertensive patients: the P.I.C.X.E.L. study rationale and design // J. Hum. Hypertens. — 2002. — Vol. 9. — P. 653-659.

Hashimoto J., Hirayama H., Hanasawa T. et al. Efficacy of combination antihypertensive therapy with low-dose indapamide: assessment by blood pressure self-monitoring at home // Clin. Exp. Hypertens. — 2005. — Vol. 4. — P. 331-341.

Heart Outcomes Prevention Evaluation Study Investigators. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE and MICRO-HOPE substudy // Lancet. — 2000. — Vol. 355. — P. 253-259.

Heerspink H., Ninomiya T., Perkovic V. et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease // European Heart Journal. — 2010. — Vol. 31. — P. 2888-2896.

Hypertension Primer. The essentials of high blood pressure. From the council on high blood pressure research American Heart Association, 1999. — 471 p.

Kang S., Wu Y.F., An N., Ren M. A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension // Clin. Ther. — 2004. — Vol. 2. — P. 257-270.

Kengne A.P., Patel A., Colagiuri S. et al. ADVANCE Collaborative Group. The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study // Diabetologia. — 2010. — Vol. 53(5). — P. 821-831.

Laurent S. Very-low-dose combination of perindopril and indapamide: efficacy on blood pressure and target-organ damage // J. Hypertens. Suppl. — 2003. — Vol. 3. — S. 11-18.

Libhaber E.N., Libhaber C.D., Candy G.P. et al. Effect of slow-release indapamide and perindopril compared with amlodipine on 24-hour blood pressure and left ventricular mass in hypertensive patients of African ancestry // Am. J. Hypertens. — 2004. — Vol. 5. — P. 428-432.

London G.M., Asmar R.G., O’Rourke M.F., Safar M.E.; REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol // J. Am. Coll. Cardiol. — 2004. — Vol. 1. — P. 92-99.

Mallion J.M., Chamontin B., Asmar R. et al. REASON Project. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study // Am. J. Hypertens. — 2004. — Vol. 3. — P. 245-251.

Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the Management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology // J. Hypertension. — 2007. — Vol. 25. — P. 1105-1187.

Mancia G., Laurent S., Agabiti-Rosei E. et al. Reapparaisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document // J. Hypertens. — 2009. — Vol. 27. — P. 2121-2158.

Matheson A.J., Cheer S.M., Goa K.L. Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension // Drugs. — 2001. — Vol. 8. — P. 1211-1229.

Mogensen C.E., Viberti G., Halimi S. et al. Preterax in Albuminuria Regression (PREMIER) Study Group. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER // Hypertension. — 2003. — Vol. 41(5). — P. 1063-1071.

Mogensen C.E. New concepts in blood pressure-lowering management in diabetic patients: the case for early ACE inhibitor combination therapy with diuretics // J. Hum. Hypertens. — 2005. — Vol. 19, Suppl. 1. — S. 15-20.

Mourad J.J., Waeber B., Zannad F. et al. investigators of the STRATHE trial. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach // J. Hypertens. — 2004. — Vol. 12. — P. 2379-2386.

Myers M.G., Asmar R., Leenen F.H., Safar M. Fixed low-dose combination therapy in hypertension — a dose response study of perindopril and indapamide // J. Hypertens. — 2000. — Vol. 3. — P. 317-325.

Ninomiya T., Perkovic V., Gallagher M. et al. PROGRESS Collaborative Group. Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial // Kidney Int. — 2008. — Vol. 73(8). — P. 963-970.

Pannier B., Guerin A., London G., Asmar R., Safar M.; REASON Study. Combination of low-dose perindopril/indapamide versus atenolol in the hypertensive patient. Effects on systolic pressure and arterial hemodynamics. REASON Study // Arch. Mal. Coeur. Vaiss. — 2002. — Vol. 6. — P. 11-16.

Safar M.E., Myers M.G., Leenen F., Asmar R. Gender influence on the dose-ranging of a low-dose perindopril-indapamide combination in hypertension: effect on systolic and pulse pressure // J. Hypertens. — 2002. — Vol. 8. — P. 1653-1661.

The ACCORD Study Group. Effects of Intensive Blood- Pressure Control in Type 2 Diabetes Mellitus // N. Engl. J. Med. — 2010. — Vol. 362. — P. 1575-1585.

UK Prospective Diabetes Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS38 // BMJ. — 1998. — Vol. 317. — P. 703-713.

UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 // BMJ. — 1998. — Vol. 317. — P. 713-720.

Zoungas S., Chalmers J., Neal B., Billot L. et al. for the ADVANCE-ON Collaborative group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes // N. Engl. J. Med. — 2014. — doi: 10.1056/NEJMoa1407963.




DOI: https://doi.org/10.22141/2224-1485.4.48.2016.76993

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru